Online inquiry

IVTScrip™ mRNA-Anti-PDCD1, BMS-936558(Cap 0, 2-Thio-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ4535MR)

This product GTTS-WQ4535MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & 2-Thio-UTP. It ecodes the monoclonal antibody that targets PDCD1 gene. The antibody can be applied in Non-Small Cell Lung Cancers (NSCLC) research.
Specifications
Product type mRNA
Modified bases 2-Thio-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_005018.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 5133
UniProt ID Q15116
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-PDCD1, BMS-936558(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) (GTTS-WQ4535MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ15215MR IVTScrip™ mRNA-Anti-TNFSF13&TNFSF13B, TACI-Fc(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA TACI-Fc
GTTS-WQ3137MR IVTScrip™ mRNA-Anti-C3&C4, APT070(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA APT070
GTTS-WQ14067MR IVTScrip™ mRNA-Anti-C5, REGN-3918(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA REGN-3918
GTTS-WQ5988MR IVTScrip™ mRNA-Anti-ITGAV&ITGB3, CNTO 095(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA CNTO 095
GTTS-WQ2709MR IVTScrip™ mRNA-Anti-CD19&CD3E, AMG103(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA AMG103
GTTS-WQ9047MR IVTScrip™ mRNA-Anti-FLT1, IMC-18F1(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA IMC-18F1
GTTS-WQ7598MR IVTScrip™ mRNA-Anti-CSF3R, G-CSF-Fc-PEG(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA G-CSF-Fc-PEG
GTTS-WQ8715MR IVTScrip™ mRNA-Anti-F3, HuMax-TF-ADC(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA HuMax-TF-ADC
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW